| 英文摘要 |
Based on the objectives of patient safety and the requirements of stem cell therapy and regenerative medicine, the article, from the perspective of ethic and the law in clinical trial, analyses and discusses the “glossy” phenomenon in providing stem cell therapy in China, and propose to formulate the promotion regulation of regenerative medicine progress of PRC in order to get rid of the anti-science problem. The seven measures should be taken into the regulation: to follow the ethics and safety standards of stem cell medicine innovation, to construct a conducive economic mechanism for stem cell therapy research, to design the good practice for obtaining informed consent of patients, to take ethical intervention for ensuring riskbenefit analysis, to supervise patient safety and report adverse events, to regulate the publication of research results, and to establish the monitoring mechanism for public governance. |
